Sunday, May 22, 2011
In 2005, a small pharmaceutical company obtained FDA approval to sell the first non-insulin product for type 1 diabetes as well as for use in type 2 diabetes. The company, Amylin Pharmaceuticals, had developed their drug, Symlin (pramlintide acetate), over 16 years of effort, and found that it improv...
I only know as much as you tell us about the process of releasing and promoting new drugs, but it seems to me that this company is desperate to make some money to justify the years of research and the cost of bringing this drug to the market. It would seems a better idea to cut their losses, dump this product and turn their attention to other avenues of research. Who would want to perform two injections for hardly any benefit. Might be popular with masochists, I suppose. Perhaps the marketing company could make use of that idea :-) I'll charge them for it though.